No Correlations Between the Development of Specific IgA and IgM Antibodies Against Anti-TNF Blocking Agents, Disease Activity and Adverse Side Reactions in Patients with Rheumatoid Arthritis

The use of tumour necrosis factor (TNF) antagonists (infliximab [IFN], etanercept [ETN], adalimumab [ADA]) has changed the course of many rheumatic diseases, including rheumatoid arthritis (RA). However, some questions concerning their safety have emerged since their approval because they can trigge...

Descripción completa

Detalles Bibliográficos
Autores principales: Benucci, Maurizio, Saviola, Gianantonio, Meacci, Francesca, Manfredi, Mariangela, Infantino, Maria, Campi, Paolo, Severino, Maurizio, Iorno, Miriam, Sarzi-Puttini, Piercarlo, Atzeni, Fabiola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Open 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3793582/
https://www.ncbi.nlm.nih.gov/pubmed/24115967
http://dx.doi.org/10.2174/1874312901307010075

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3793582/
https://www.ncbi.nlm.nih.gov/pubmed/24115967
http://dx.doi.org/10.2174/1874312901307010075

Ejemplares similares